Medtech company Atomo Diagnostics (ASX: AT1) has been granted regulatory approval in Australia for their patented AtomoRapid HIV (1&2) rapid diagnostic kit which will enable testing for HIV with just one drop of blood. The approval granted by the Therapeutic Goods Association (TAG) enables Atomo to commence distribution of the diagnostic test to medical professionals
Read More
Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on
Read More
It may soon be easier for prostate cancer to be diagnosed at an early stage with Telix Pharmaceuticals (ASX: TLX) having submitted their radiopharmaceutical imaging technology to the Food and Drug Administration for approval. The New Drug Application (NDA) comes after completing clinical trials across more than 600 patients which builds on peer-reviewed clinical research
Read More
With only one company set to list this month, it appears that the volatility that surrounds the ASX is prompting some companies to delay listing until some degree of normality in financial markets is restored. One company brave enough to face the current environment is Atomo Diagnostics Limited (Proposed ASX: AT1). The Sydney-based medical diagnostics
Read More
Melbourne-based drug development company AdAlta (ASX: 1AD) has been selected by GE Healthcare, one of the world’s largest healthcare companies, to develop ‘i-bodies’ which GE can use as imaging agents. One-tenth of the size of regular antibodies, i-bodies are a new class of human protein therapeutic which can be applied as a therapeutic drug to
Read More